share_log

冠昊生物(300238.SZ)：核心业务为材料、药业、细胞三大业务板块

Guanhao Biology (300238.SZ): The core business is the three major business segments of materials, pharmaceuticals, and cells

Gelonghui Finance ·  May 8 04:20

Gelonghui, May 8 | Guanhao Biology (300238.SZ) said on the investor interactive platform that the company's core business is the three major business segments: materials, pharmaceuticals, and cells. The main products in the field of materials include biotype dural (spine) membrane patches, B-type cerebral (spine) membrane patches, thoracic surgical repair films, sterile biological wound protection films, and Ario breast patches, which can be widely used in neurosurgery, thoracic surgery, dermatology, orthopedics, plastic surgery, etc. Benvermide, the main product in the pharmaceutical industry, can treat inflammatory and autoimmune diseases such as psoriasis and atopic dermatitis. The cell field mainly includes cell storage, cellular cartilage therapy, etc.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment